Melanoma Clinical Trials

A Phase 2 Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) with Lifileucel infusion (LN-144) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen.

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as v-raf murine …

A Phase II Study of Combining Talimogene Laherparepvec T-VEC (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

The purpose of this study is to test any good and bad effects of the combination of study drugs called MK-3475 (pembrolizumab) and talimogene laherparepvec (T-VEC) in melanoma patients.

Cancer Drug Development Program  

Develop a new cancer drug targeting multiple types of tumors.

Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma

This study is for women with advanced or recurrent endometrial cancer using Pembrolizumab in combination with Carboplatin and Paclitaxel chemotherapy.

A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475), to look for the highest dose of pembrolizumab that can be given safely without serious side effects, to find out how pembrolizumab is absorbed and broken down, and to …

A Study to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

BAN2401 is an investigational study drug which is being studied in people who have early AD (Alzheimer's disease), with mild cognitive (thinking) impairment or mild dementia. People with AD have a build-up of abnormal protein known as amyloid in their brains.  This build up may lead to impairment in memory …

None

None